|Study Period:||2018 - 2026|
|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The global animal biotechnology market is expected to register a CAGR of 6.5% during the forecast period.
As per the data from the Centres for Disease Control and Prevention (CDC), in 2020, cats, dogs, and a few other types of animals were at potential risk of acquiring the Coronavirus. The virus was recently detected on minks on multiple farms in the Netherlands. Several studies are being undertaken to understand the connection between animals and the human transmission of the virus.
Moreover, the COVID-19 pandemic had a dramatic effect throughout the world on animal healthcare systems. Due to the fear of the virus, people are generally seen avoiding visits to veterinary hospitals. Thus, the reduction of hospital visits results in delayed diagnosis and treatment for animals, leading to a decline in demand for animal health management products.
Globally, biotechnology has improved animal feed, produced vaccines for livestock, and improved diagnostics for diseases such as bovine spongiform encephalopathy (BSE), foot-and-mouth disease, and salmonella.
A significant rise in focus toward cloning and transgenic animals is expected to propel market growth. For instance, according to a research article by NishuNishu et al., published in Animal Biotechnology 2020, globally, rapidly growing technologies in genomic knowledgebase have tremendously fastened the process of transgenesis. In addition, alteration of the transgenic animal genome is essential to understand diseases in animals.
As per the report published by the US Food and Drug Administration (FDA), in 2017, scientists successfully cloned many livestock species, such as cattle, swine, sheep, and goats. Globally, animal cloning has gained popularity and acceptance as a method to produce genetically identical animals, which is expected to fuel market growth.
In addition, as per the Animal Free Research UK, in 2019, around 1,729,646 animal experiments were performed in the United Kingdom, including 4,227 experiments on 2,679 dogs and 2,850 experiments on 2,156 primates, 131 experiments on 28 cats, and 10,512 experiments on 43 horses, respectively.
The market players in the animal biotechnology market are involved in various growth strategies, such as collaborations, partnerships, agreements, and mergers and acquisitions, in order to enhance their market presence. For instance, in 2020, Merck Animal Health signed a partnership agreement with Automazioni VX, Inc. (US), aiming to introduce Innoject Pro, a newly designed subcutaneous chick vaccination technology. The technology will be utilized in combination with Merck Animal Health’s Innovax range of vaccines, which is used for protection against infectious diseases.
In addition to the aforementioned factors, increasing R&D activities by major market players and the rising number of regulatory approvals are expected to propel the market growth over the forecast period.
Scope of the Report
As per the scope of the report, animal biotechnology refers to the branch of biotechnology, which deals with the molecular biology techniques for producing genetically engineered animals (whose genomes are modified), to make them suitable for pharmaceutical, industrial, or agricultural applications. The animal biotechnology market is segmented by Product Type (Diagnostic Tests, Reproductive & Genetic Products, Vaccines, and Drugs), Application (Development of Animal Pharmaceuticals, Food Safety and Drug Development, Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.
|By Product Type|
|Reproductive & Genetic Products|
|Development of Animal Pharmaceuticals|
|Food Safety and Drug Development|
Key Market Trends
Vaccines Segment is Expected to Show Better Growth Over the Forecast Period
The growth of the vaccine segment is mainly attributed to the rising burden of animal diseases. These diseases are naturally transmitted from animals to humans due to contaminated food and water consumption or direct contact with infected animals or humans. Vaccination is an effective way to reduce disease burden in animals, and it plays an essential role in preventive healthcare and disease control.
As per research studies, diverse coronaviruses can infect domestic species, from cattle, pigs, and poultry, to cats and dogs. Many of these infections are controlled by routine vaccination. Though research on SARS-Cov-2 in animals is limited, studies are underway to learn more about this virus and its effect on different animals.
Furthermore, globally, national animal disease control programs were reduced or even suspended. National activities on outbreak investigations, animal disease surveillance, and vaccination campaigns were not implemented. For instance, Australia’s Minister of Agriculture said that COVID-19 restrictions would affect the industry and the government’s response to an outbreak of African swine fever. In addition, efforts to control African swine fever in Papua New Guinea were challenging to implement due to the COVID-19 lockdown in the country.
According to a research article by Andrew W. Byrne et al., published in Frontiers in Veterinary Science 2019, bovine tuberculosis (bTB) remains a prominent zoonotic pathogen globally, with significant impacts on animal and human health and economic well-being. Moreover, the increasing demand for meat and animal-based products, rising pet adoption, and increasing awareness regarding animal health are expected to fuel the growth of the vaccine segment over the forecast period.
The market players are also investing in vaccine development, which is driving the market growth. For instance, in 2019, Boehringer Ingelheim started to develop the largest biotechnology site for veterinary vaccines in France, as their demand increased with growth in poultry consumption. The company invested EUR 200 million at the 15,000 m2 facility in Lyon, France. Thus, considering the above-mentioned factors, it is expected to fuel the segment growth over the forecast period.
To understand key trends, Download Sample Report
North America Dominates the Market and is Expected to do the Same over the Forecast Period
The major factors driving the animal biotechnology market include the increase in adoption of companion animals, increasing prevalence of diseases such as zoonosis, availability of advanced veterinary healthcare infrastructure in the region, and presence of key market players in North America.
In the United States, the COVID-19 pandemic directly or indirectly disrupts activities to keep livestock animals healthy, including preventing and controlling diseases. Due to labor shortages, there was a reduced capacity to work on animal health activities, such as vaccination, maintaining good biosecurity, medical treatment of sick animals, and prophylactic treatment. For instance, according to the United States Food and Drug Administration (USFDA), 6 of the 32 animal drug companies that make finished drugs or source active pharmaceutical ingredients in China for the US market, have indicated that the supply chain disruptions could soon lead to shortages of medicines (American Veterinary Medical Association).
There are also increasing initiatives and campaigns implemented by the Canadian government to promote animal health, which may boost the demand for animal diagnostics in the coming years. For instance, the Canadian Veterinary Medical Association promotes animal welfare to ensure the optimal health of animals. Such activities are likely to influence the studied market growth in Canada.
The data published by the American Pet Products Association in 2018 states that the total pet healthcare expenditure has been estimated to be USD 72.13 billion, while that in 2017 was found to be USD 69.51 billion.
In February 2020, Zoetis Inc. acquired Ethos Diagnostic Science, a veterinary reference lab. By entering the veterinary reference laboratory space through the acquisition of both Phoenix Lab and ZNLabs in 2019, Zoetis continues to grow its diagnostics presence to offer comprehensive and enhanced value to veterinarians in the United States. In addition, the growing awareness about animal health among pet owners, rising government initiatives, and rise in product innovation (such as new vaccine launches) are some other factors propelling the growth of the animal biotechnology market in North America.
To understand geography trends, Download Sample Report
The animal biotechnology market is moderately consolidated and consists of few major players who are currently dominating the market. Some of the market players include Bayer AG, Boehringer Ingelheim GmbH, Merck & Co.,Inc., Zoetis Inc., Virbac, and others.
In June 2020, Chanelle Pharma Group received the United States Food and Drugs Administration's (FDA) approval to manufacture Spot On in the US market. Spot On is a topical treatment used to protect cats and dogs against parasites.
In April 2020, Heska Corporation acquired Scil Animal Care, to emerge as a global leader in veterinary point-of-care diagnostics.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing R&D Activities by Major Market Players
4.2.2 Growing Focus Towards Cloning & Transgenic Animals
4.3 Market Restraints
4.3.1 Ethical Issues Associated with Animal Biotechnology Products
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Diagnostic Tests
5.1.2 Reproductive & Genetic Products
5.2 By Application
5.2.1 Development of Animal Pharmaceuticals
5.2.2 Food Safety and Drug Development
5.2.3 Other Applications
5.3.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.3.4 Middle East and Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle East and Africa
5.3.5 South America
126.96.36.199 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Bayer AG
6.1.2 Biogenesis Bago
6.1.3 Boehringer Ingelheim GmbH
6.1.4 Ivaoes, LLC
6.1.5 Merck & Co.,Inc.
6.1.6 Pfizer Inc.
6.1.7 Santa Cruz Biotechnology, Inc.
6.1.9 Zoetis Inc.
6.1.10 Idexx Laboratories
6.1.12 Heska Corporation
6.1.13 INDICAL Bioscience GmbH
6.1.14 BioChek BV
6.1.15 Randox Laboratories Ltd
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Animal Biotechnology Market market is studied from 2018 - 2026.
What is the growth rate of Global Animal Biotechnology Market?
The Global Animal Biotechnology Market is growing at a CAGR of 6.5% over the next 5 years.
Which region has highest growth rate in Global Animal Biotechnology Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Animal Biotechnology Market?
North America holds highest share in 2020.
Who are the key players in Global Animal Biotechnology Market?
Bayer AG, Boehringer Ingelheim GmbH, Merck & Co.,Inc., Zoetis Inc., Virbac are the major companies operating in Global Animal Biotechnology Market.